[1]Patent:WO2014/43446,2014,A1
[2]JournalofMedicinalChemistry,2019,vol.62,p.6482-6494
[1]Patent:WO2014/43446,2014,A1
[2]JournalofMedicinalChemistry,2019,vol.62,p.6482-6494
[1]Patent:WO2014/43446,2014,A1
[2]JournalofMedicinalChemistry,2019,vol.62,p.6482-6494
[1]Patent:WO2014/43446,2014,A1
[2]JournalofMedicinalChemistry,2019,vol.62,p.6482-6494
[1]Patent:WO2014/43446,2014,A1
[2]JournalofMedicinalChemistry,2019,vol.62,p.6482-6494
Title: Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[dthiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494.